West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

West Pharmaceutical Services, Inc.

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Align Technology, Inc.

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Anika Therapeutics, Inc.

DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide. The company operates through two segments, Technologies & Equipment, and Consumables. The Technologies & Equipment segment provides dental equipment, such as treatment centers, imaging equipment, motorized dental handpieces, and other instruments for dental practitioners and specialists; dental CAD/CAM technologies for dental offices to support various digital dental procedures, including dental restorations; dentist-directed clear aligner solutions, SureSmile, and direct-to-consumer clear aligner solutions, as well as high frequency vibration technology device; implants; and urology catheters and other healthcare-related consumable products. The Consumables segment offers endodontic products comprising drills, filers, sealers, irrigation needles, and other tools or single-use solutions, which support root canal procedures; restorative products that include artificial teeth, dental ceramics, digital dentures, precious metal dental alloys, and crown and bridge porcelain products. It also provides small equipment products, which comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, impression materials, teeth whiteners, and topical fluoride. The company was founded in 1877 and is headquartered in Charlotte, North Carolina.

DENTSPLY SIRONA Inc.

West Pharmaceutical Services, Inc. is a provider of innovative, high-quality injectable solutions and services, committed to improving health for patients worldwide.

Metric
Company Name	West Pharmaceutical Services, Inc.	Align Technology, Inc.	Anika Therapeutics, Inc.	DENTSPLY SIRONA Inc.
Symbol	WST	ALGN	ANIK	XRAY
MSH ID	COM:WESTPHARMA	COM:ALIGNTECH	COM:ANIKA	COM:DENTSPLYSIRONA
Market	STOCKS	STOCKS	STOCKS	STOCKS
Sector	Healthcare	Healthcare	Healthcare	Healthcare
Industry	Medical - Instruments & Supplies	Medical - Devices	Medical - Devices	Medical - Instruments & Supplies
Country	US	US	US	US
Stage
Employee Count	10.60K	21.67K	357	15K
Website	westpharma.com	aligntech.com	anikatherapeutics.com	dentsplysirona.com
LinkedIn		align-technology
Founders

Metric
Market Cap	23.41B	18.75B	389.26M	5.07B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.95B	3.86B	166.66M	3.96B
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.13B	2.71B	103.09M	2.09B
EBITDA	875.70M	643.34M	-11.21M	638M
Operating Income	676M	643.34M	-25.45M	295M
Net Income	593.40M	445.05M	-82.67M	-132M
EPS	7.98	5.82	-5.64	-0.62
Diluted EPS	7.88	5.81	-5.64	-0.62
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.38	0.70	0.62	0.53
Operating Profit Margin	0.23	0.17	-0.08	-0.02
EBITDA Margin	0.30	0.17	-0.07	0.16
Net Profit Margin	0.20	0.12	-0.44	-0.02
Return on Equity	0.21	0.12	-0.32	-0.03
Return on Assets	0.16	0.08	-0.28	-0.01
Return on Capital Employed	0.22	0.17	-0.06	-0.01

COM:WESTPHARMA

West Pharmaceutical Services, Inc.

Last Close

320.88

22/11 21:00

Market Cap

23.41B

Beta: -

Volume Today

557.15K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	52.81	46.94	-14.02	-32.49
P/B Ratio	10.30	5.75	1.27	2.10
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	9.76	6.15	2.52	2.31
EV Multiple	34.90	38.23	-28.38	10.43

Metric
Days Sales Outstanding	64.74	85.38	77.51	60.18
Days Payables Outstanding	44.24	35.74	48.25	51.55
Days Inventory Outstanding	87.15	94.07	295.29	121.21
Operating Cycle	150.56	195.74	369.15	214.15
Cash Conversion Cycle	104.66	159.65	311.81	154.91
Asset Turnover	0.82	0.64	0.64	0.56

Metric
Operating Cash Flow	776.50M	785.78M	-1.79M	377M
Free Cash Flow	414.50M	608.06M	-7.21M	228M
Cash Flow to Debt	3.31	6.21	0.32	0.25
Operating Cash Flow/Sales	0.26	0.20	0.05	0.14
Free Cash Flow Yield	0.01	0.03	-0.03	0.03

Metric
Cash & Equivalents	853.90M	937.44M	72.87M	334M
Accounts Receivable	4M	-104.61M	-1.30M	-58M
Inventory	434.70M	296.90M	46.39M	624M
Goodwill	108.50M	419.53M	7.57M	2.44B
Debt to Capitalization	0.10	0.05	0.12	0.42
Debt to Assets	0.08	0.04	0.08	0.29
Current Ratio	3.70	1.18	5.59	1.57
Quick Ratio	2.03	1.09	3.96	0.97

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.03	0.09	0.01
R&D to Revenue	0.02	0.09	0.20	0.05
SG&A to Revenue